No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 38 of the 40 quarters in the window, leaving 2 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Processa Pharmaceuticals, Inc. (PCSA) stock was $1.52 as of Oct 6, 2026, 1:54 PM EDT, up 1.95% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -71.9% · 3-year avg -76.2%/yr · 5-year avg -79.3%/yr
Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States.
Biotechnology · Vero Beach, FL
Next Earnings Date
Oct 29, 2026
23 days away
EPS Estimate
-1.00
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.75
vs Estimate
$-2.00
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PCSA | $4.20M | $1.52 | +1.95% | -71.87% | -79.32% | -48.59% | N/A |
| 2AIDX | $4.23M | $0.34 | -2.10% | N/A | N/A | N/A | vs PCSA |
| 3SXTP | $4.15M | $1.18 | -18.06% | -74.48% | N/A | N/A | vs PCSA |
| 4GRI | $4.09M | $1.87 | -2.09% | -96.44% | -95.39% | N/A | vs PCSA |
| 5CLGN | $4.34M | $3.35 | -1.76% | -85.66% | -53.69% | N/A | vs PCSA |
| 6APVO | $3.97M | $1.81 | +0.79% | -92.21% | -95.30% | -80.35% | vs PCSA |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.52
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.00 | $-1.00 | $-1.00 | 1 |
| Quarter ending Dec 2026 | $-0.75 | $-0.75 | $-0.75 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-6.00 | $-6.00 | $-6.00 | 1 |
| FY 2027 | $-5.25 | $-5.25 | $-5.25 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $10.01M | $10.01M | $10.01M | 1 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $10.36M |
| $10.36M |
| $10.36M |
| 1 |
